Ken Griffin I Bio, Inc. Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.23 - $160.0 $117,917 - $82 Million	-512,685 Reduced 72.76%	191,939 $33,000
Q2 2022 Aug 15, 2022	BUY	$0.23 - $0.46 $114,588 - $229,177	498,211 Added 241.37%	704,624 $186,000
Q1 2022 May 16, 2022	SELL	$0.3 - $0.61 $35,268 - $71,712	-117,562 Reduced 36.29%	206,413 $88,000
Q4 2021 Feb 14, 2022	BUY	$0.55 - $1.04 $133,602 - $252,629	242,913 Added 299.66%	323,975 $178,000
Q3 2021 Nov 15, 2021	BUY	$1.06 - $1.52 $60,087 - $86,162	56,686 Added 232.55%	81,062 $86,000
Q2 2021 Aug 16, 2021	SELL	$1.22 - $1.65 $33,791 - $45,701	-27,698 Reduced 53.19%	24,376 $36,000
Q1 2021 May 17, 2021	BUY	$1.18 - $2.62 $61,447 - $136,433	52,074 New	52,074 $80,000
Q1 2020 May 15, 2020	SELL	$0.22 - $2.45 $25,936 - $288,832	-117,891 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.11 - $0.58 $6,705 - $35,354	60,956 Added 107.06%	117,891 $29,000
Q2 2019 Aug 14, 2019	BUY	$0.71 - $0.91 $2,622 - $3,361	3,694 Added 6.94%	56,935 $40,000
Q1 2019 May 15, 2019	BUY	$0.75 - $1.0 $19,992 - $26,656	26,656 Added 100.27%	53,241 $0
Q4 2018 Feb 14, 2019	BUY	$0.57 - $1.05 $15,153 - $27,914	26,585 New	26,585 $19,000

Ticker IBIO
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,006,580
Market Cap $24M
Description
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.